<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-JB9BG0WR/6011069f-2e55-428a-be51-16dcfd347b76/HTML"><dcterms:extent>44 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-JB9BG0WR/2fa078b4-4248-4d4f-992b-bb031a36f193/PDF"><dcterms:extent>238 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-JB9BG0WR/acd0ec1b-48a0-4db6-8ad0-22c5ea9dd18b/TEXT"><dcterms:extent>41 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-JB9BG0WR"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2012</dcterms:issued><dc:creator>Kocbek, Petra</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:63</dc:format><dc:format xml:lang="sl">str. 75-81</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:3243633</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-JB9BG0WR</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">dostavni sistemi</dc:subject><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="sl">nanoantibiotiki</dc:subject><dc:subject xml:lang="sl">nanotehnologija</dc:subject><dc:subject xml:lang="sl">nanoteranostiki</dc:subject><dc:subject xml:lang="sl">nanovlakna</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Novosti na področju farmacevtske nanotehnologije| Novelties in the field of pharmaceutical nanotechnology|</dc:title><dc:description xml:lang="sl">Pharmaceutical nanotechnology has been under intensive development for more than four decades and shows a significant impact on the diagnosis and treatment of many diseases. Its main goal is development of modern nanodelivery systems for more effective therapy and reduced occurrence of side effects. The results of the current development are ŽsmartŽ bioresponsive nanodelivery systems, nanosystems for active targeting and nanosystems for targeting on subcellular level. Novel nanodelivery systems can overcome barriers in the body and enable the drug delivery to the locations which are out of reach for classical formulations (e.g. brain delivery). New formulation methods have also emerged. The main focus being on self-assembly technologies, which enable incorporation of modern macromolecular drugs (peptides, proteins, genes). All these and many other innovations in the field of pharmaceutical nanotechnology promise better monitoring and therapy of nowadays incurable or poorly treatable diseases, resulting in improved patient's quality of life</dc:description><dc:description xml:lang="sl">Farmacevtska nanotehnologija se intenzivno razvija že dobra štiri desetletja in ima pomemben vpliv na odkrivanje in zdravljenje številnih bolezni. Njen cilj je razviti sodobne nanodostavne sisteme, ki bodo povečali učinkovitost zdravljenja in zmanjšali pojav stranskih učinkov. Tako so rezultat razvoja &gt;&gt;pametni&lt;&lt; bioodzivni nanodostavni sistemi, nanosistemi za aktivno ciljanje in nanosistemi za ciljanje na subceličnem nivoju. Novi nanodostavni sistemi omogočajo premagovanje barier v organizmu in vnos učinkovin na mesta, ki so s klasičnimi farmacevtskimi oblikami nedostopna (npr. vnos v možgane). Novosti so tudi na področju metod za izdelavo nanosistemov, kjer so v ospredju metode,ki temeljijo na samozdruževanju gradnikov in omogočajo vgrajevanje sodobnih makromolekularnih učinkovin (peptidi, proteini, geni). Vse omenjene in še številne druge novosti na področju farmacevtske nanotehnologije obetajo boljše spremljanje in zdravljenje danes neozdravljivih ali težko ozdravljivih bolezni ob sočasno izboljšani kakovosti bolnikovega življenja</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-JB9BG0WR"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-JB9BG0WR" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-JB9BG0WR/2fa078b4-4248-4d4f-992b-bb031a36f193/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-JB9BG0WR/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-JB9BG0WR" /></ore:Aggregation></rdf:RDF>